Reuters logo
Athersys stem-cell therapy for bowel disease fails in study
April 28, 2014 / 11:21 AM / 3 years ago

Athersys stem-cell therapy for bowel disease fails in study

April 28 (Reuters) - Athersys Inc said its experimental stem-cell therapy for treating an inflammatory bowel disease failed to show any benefit in patients in a mid-stage trial.

The trial, conducted by Athersys’s partner Pfizer Inc , did not show a statistically significant reduction in the severity of the disease and rectal bleeding as compared to placebo. (Reporting by Esha Dey in Bangalore; Editing by Saumyadeb Chakrabarty)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below